https://m2.mtmt.hu/ eng 2026-05-31 14:05 JournalArticle 3251042 VALIDATED true 0 2018-07-25T22:20:07.000+0000 false 3251042 2026-05-26T09:00:20.741+0000 2020-12-22T20:31:36.236+0000 2017-07-25T09:41:48.000+0000 true 10022032 Szebényi Kornélia /api/author/10022032 Author Kornélia Szebényi (Őssejtbiológia) true 10022032 2026-03-05T11:57:31.899+0000 2020-01-17T13:45:12.011+0000 true 10056781 Bikádi Katalin /api/admin/10056781 Admin Katalin Bikádi (Állatorvostud. Egy. 4 - INAKTÍV, admin) true 10056781 2020-03-05T12:59:22.490+0000 true 10069303 Patkós Ilona /api/admin/10069303 Admin Ilona Patkós (xSE_KK_Admin5_PI, admin) true Admin 10065569 /api/admin/10065569 Éva Pécsi (MTMT Közp 2,3, admin) Pécsi Éva true true 2026-04-14T13:01:34.757+0000 true false true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Journal Article 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Article (Journal Article) 101 true 10000059 true 1 /api/category/1 Category Scientific true 1 Furedi, A true true /api/journal/2406 REVIEWED JOURNAL OF CONTROLLED RELEASE 0168-3659 1873-4995 true false 2406 false 2406 true 0168-3659 1873-4995 Journal FOREIGN 261 287 296 287 10 2017 Success of cancer treatment is often hampered by the emergence of multidrug resistance (MDR) mediated by P-glycoprotein (ABCB1/Pgp). Doxorubicin (DOX) is recognized by Pgp and therefore it can induce therapy resistance in breast cancer patients. In this study our aim was to evaluate the susceptibility of the pegylated liposomal formulation of doxorubicin (PLD/Doxil(R)/Caelyx(R)) to MDR. We show that cells selected to be resistant to DOX are cross-resistant to PLD and PLD is also ineffective in an allograft model of doxorubicin-resistant mouse B-cell leukemia. In contrast, PLD was far more efficient than DOX as reflected by a significant increase of both relapse-free and overall survival of Brca1-/-;p53-/- mammary tumor bearing mice. Increased survival could be explained by the delayed onset of drug resistance. Consistent with the higher Pgp levels needed to confer resistance, PLD administration was able to overcome doxorubicin insensitivity of the mouse mammary tumors. Our results indicate that the favorable pharmacokinetics achieved with PLD can effectively overcome Pgp-mediated resistance, suggesting that PLD therapy could be a promising strategy for the treatment of therapy-resistant breast cancer patients. true true 2017 (Szebényi Kornélia (Őssejtbiológia); 2017.07.25. 11:40:23) true true true false true false GREEN GREEN 2026-05-26 true http://real.mtak.hu/74947 94 0 94 70 56 81 92 72 92 93 93 69 69 70 24 0 94 70 94 70 0 8 8 Folyóiratcikk Journal Article 24 65 Könyvrészlet Chapter in Book 25 29 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2018 0 6 5 6 5 2019 0 9 8 9 8 2020 0 14 9 14 9 2021 0 13 10 13 10 2022 0 16 13 16 13 2023 0 13 9 13 9 2024 0 10 8 10 8 2025 0 9 6 9 6 2026 0 4 2 4 2 D1 false 10002293,10050407,10014805,10059335,10032964,10032787,10053930,10022032,10001932 false false false 2018-03-12T08:36:56.000+0000 2017-07-25T09:46:09.000+0000 Enzimológiai Intézet (TTK); Kórélettani és Onkológiai Tanszék (ÁTE); Műszercentrum (TTK); Országos Onkológiai Intézet 13 75 4 13 0 true 10065569 Language 10002 /api/language/10002 English Angol English true 2 true PersonAuthorship 9220404 /api/authorship/9220404 Furedi, A [Füredi, András (Tumorbiológia, dr...), author] Institute of Enzymology (RCNS) 1 0.07692308 true false Author 10032787 /api/author/10032787 András Füredi (Tumorbiológia, drog rezisztencia) Füredi András true 10032787 true Furedi A true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641619 true PersonAuthorship 9220405 /api/authorship/9220405 Szebenyi, K [Szebényi, Kornélia (Őssejtbiológia), author] 2 0.07692308 false false Author 10022032 /api/author/10022032 Kornélia Szebényi (Őssejtbiológia) Szebényi Kornélia true 10022032 true Szebenyi K true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641618 true PersonAuthorship 9220406 /api/authorship/9220406 Toth, S [Tóth, Szilárd (Molekuláris biológia), author] 3 0.07692308 false false Author 10032964 /api/author/10032964 Szilárd Tóth (Molekuláris biológia) Tóth Szilárd true 10032964 true Toth S true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641617 true PersonAuthorship 9220407 /api/authorship/9220407 Cserepes, M [Cserepes, Tamás Mihály (tumorbiológia, mo...), author] 4 0.07692308 false false Author 10050407 /api/author/10050407 Tamás Mihály Cserepes (tumorbiológia, molekuláris biológia) Cserepes Tamás Mihály true 10050407 true Cserepes M true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641616 true PersonAuthorship 9220408 /api/authorship/9220408 Hamori, L [Hámori, Lilla (Tumorsejtbiológia), author] Institute of Enzymology (RCNS) 5 0.07692308 false false Author 10053930 /api/author/10053930 Lilla Hámori (Tumorsejtbiológia) Hámori Lilla true 10053930 true Hamori L true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641615 true PersonAuthorship 9220409 /api/authorship/9220409 Nagy, V [Nagy, Veronika (Tumorbiológia), author] 6 0.07692308 false false Author 10053931 /api/author/10053931 Veronika Nagy (Tumorbiológia) Nagy Veronika true 10053931 true Nagy V true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641614 true PersonAuthorship 9220410 /api/authorship/9220410 Karai, E [Karai, Edina (onkológia), author] Department of Patophysiology and Oncology (UVMB) 7 0.07692308 false false Author 10059335 /api/author/10059335 Edina Karai (onkológia) Karai Edina true 10059335 true Karai E true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641613 true PersonAuthorship 9220411 /api/authorship/9220411 Vajdovich, P [Vajdovich, Péter (Állatorvosi belgy...), author] Department of Patophysiology and Oncology (UVMB) 8 0.07692308 false false Author 10002293 /api/author/10002293 Péter Vajdovich (Állatorvosi belgyógyászat, laboratóriumi diagnosztika, hematológia, onkológia) Vajdovich Péter true 10002293 true Vajdovich P true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641612 true PersonAuthorship 9220412 /api/authorship/9220412 Imre, T [Imre, Timea (Tömegspektrometria), author] Instrumentation Center (RCNS) 9 0.07692308 false false Author 10014805 /api/author/10014805 Timea Imre (Tömegspektrometria) Imre Timea true 10014805 true Imre T true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641611 true PersonAuthorship 9220413 /api/authorship/9220413 Szabo, P [Szabó, Pál Tamás (Tömegspektrometria), author] Instrumentation Center (RCNS) 10 0.07692308 false false Author 10014589 /api/author/10014589 Pál Tamás Szabó (Tömegspektrometria) Szabó Pál Tamás true 10014589 true Szabo P true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641610 true PersonAuthorship 9220414 /api/authorship/9220414 Szuts, D [Szüts, Dávid (Molekuláris biológia), author] Institute of Enzymology (RCNS) 11 0.07692308 false false Author 10026660 /api/author/10026660 Dávid Szüts (Molekuláris biológia) Szüts Dávid true 10026660 true Szuts D true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641609 true PersonAuthorship 9220415 /api/authorship/9220415 Tovari, J [Tóvári, József (Daganatbiológia, ...), author] National Institute of Oncology 12 0.07692308 false false Author 10009941 /api/author/10009941 József Tóvári (Daganatbiológia, áttétképzés) Tóvári József true 10009941 true Tovari J true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641608 true PersonAuthorship 9220416 /api/authorship/9220416 Szakacs, G ✉ [Szakács, Gergely (Biokémia, membrán...), author] Institute of Enzymology (RCNS) 13 0.077 false true true Author 10001932 /api/author/10001932 Gergely Szakács (Biokémia, membránbiológia) Szakács Gergely true 10001932 true Szakacs G true false false AuthorshipType 1 /api/authorshiptype/1 Author 0 true 0 true false 26641607 true PublicationIdentifier 1216517 /api/publicationidentifier/1216517 DOI: 10.1016/j.jconrel.2017.07.010 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true PAY false IDENTICAL 10.1016/j.jconrel.2017.07.010 https://doi.org/10.1016/j.jconrel.2017.07.010 false 1616856 true PublicationIdentifier 1216519 /api/publicationidentifier/1216519 REAL: 74947 SwordSource 36 /api/publicationsource/36 REAL PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true REAL REAL http://real.mtak.hu/@@@ true true 36 true GREEN true NO 74947 http://real.mtak.hu/74947 false 1728214 true PublicationIdentifier 1216515 /api/publicationidentifier/1216515 WoS: 000406860400025 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true false IDENTICAL 000406860400025 https://www.webofscience.com/wos/woscc/full-record/000406860400025 false 1736235 true PublicationIdentifier 1216516 /api/publicationidentifier/1216516 Scopus: 85023647981 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true false IDENTICAL 85023647981 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85023647981 false 1774260 true PublicationIdentifier 1216518 /api/publicationidentifier/1216518 PubMed: 28700899 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true false IDENTICAL 28700899 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28700899&dopt=Abstract false 1616857 true PublicationIdentifier 31583213 /api/publicationidentifier/31583213 Other URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023647981&doi=10.1016%2Fj.jconrel.2017.07.010&partnerID=40&md5=4f2050aa52706d40d3ec2a4bb16c2111 PlainSource 40 /api/publicationsource/40 Other URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true NONE IDENTICAL https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023647981&doi=10.1016%2Fj.jconrel.2017.07.010&partnerID=40&md5=4f2050aa52706d40d3ec2a4bb16c2111 https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023647981&doi=10.1016%2Fj.jconrel.2017.07.010&partnerID=40&md5=4f2050aa52706d40d3ec2a4bb16c2111 false true Classification 12125 /api/classification/12125 Basic medicine true true Classification 10293 /api/classification/10293 Chemical sciences true true SjrRating 10720833 /api/sjrrating/10720833 sjr:D1 (2017) Scopus - Pharmaceutical Science JOURNAL OF CONTROLLED RELEASE 0168-3659 1873-4995 5 0.1 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3003 /api/classificationexternal/3003 Scopus - Pharmaceutical Science true 3003 true D1 DIRECT true true Reference 2241561 /api/reference/2241561 1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012 (2012) CA Cancer J. Clin., 62, pp. 10-29 1 false true Reference 2241562 /api/reference/2241562 2. Wilson, T.R., Johnston, P.G., Longley, D.B., Anti-apoptotic mechanisms of drug resistance in cancer (2009) Curr. Cancer Drug Targets, 9, pp. 307-319 2 false true Reference 2241563 /api/reference/2241563 3. Colombo, P.-E., Milanezi, F., Weigelt, B., Reis-Filho, J.S., Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction (2011) Breast Cancer Res. BCR., 13, p. 212 3 false true Reference 2241564 /api/reference/2241564 4. O'Shaughnessy, J., Extending survival with chemotherapy in metastatic breast cancer (2005) Oncologist, 10, pp. 20-29 4 false true Reference 2241565 /api/reference/2241565 5. Cortes, J., Baselga, J., Targeting the microtubules in breast cancer beyond taxanes: the epothilones (2007) Oncologist, 12, pp. 271-280 5 false true Reference 2241566 /api/reference/2241566 6. Castells, M., Thibault, B., Delord, J.-P., Couderc, B., Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death (2012) Int. J. Mol. Sci., 13, pp. 9545-9571 6 false true Reference 2241567 /api/reference/2241567 7. Gottesman, M.M., Mechanisms of cancer drug resistance (2002) Annu. Rev. Med., 53, pp. 615-627 7 false true Reference 2241568 /api/reference/2241568 8. Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: role of ATP-dependent transporters (2002) Nat. Rev. Cancer, 2, pp. 48-58 8 false true Reference 2241569 /api/reference/2241569 9. Pirker, R., Wallner, J., Götzl, M., Gsur, A., Geissler, K., Havelec, L., Knapp, W., Lechner, K., MDR1 RNA expression is an independent prognostic factor in acute myeloid leukemia (1992) Blood, 80, pp. 557-559 9 false true Reference 2241570 /api/reference/2241570 10. Doxani, C., Voulgarelis, M., Zintzaras, E., MDR1 mRNA expression and MDR1 gene variants as predictors of response to chemotherapy in patients with acute myeloid leukaemia: a meta-analysis (2013) Biomark. Biochem. Indic. Expo. Response Susceptibility Chem., 18, pp. 425-435 10 false true Reference 2241571 /api/reference/2241571 11. Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., Fiere, D., Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis (1992) Blood, 79, pp. 473-476 11 false true Reference 2241572 /api/reference/2241572 12. Karaszi, E., Jakab, K., Homolya, L., Szakacs, G., Hollo, Z., Telek, B., Kiss, A., Sarkadi, B., Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia (2001) Br. J. Haematol., 112, pp. 308-314 12 false true Reference 2241573 /api/reference/2241573 13. Liu, X., Holstege, H., van der Gulden, H., Treur-Mulder, M., Zevenhoven, J., Velds, A., Kerkhoven, R.M., Peterse, J.L., Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer (2007) Proc. Natl. Acad. Sci., 104, pp. 12111-12116 13 false true Reference 2241574 /api/reference/2241574 14. Rottenberg, S., Borst, P., Drug resistance in the mouse cancer clinic (2012) Drug Resist. Updat., 15, pp. 81-89 14 false true Reference 2241575 /api/reference/2241575 15. Rottenberg, S., Jonkers, J., Modeling therapy resistance in genetically engineered mouse cancer models (2008) Drug Resist. Updat., 11, pp. 51-60 15 false true Reference 2241576 /api/reference/2241576 16. Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., de Bono, J.S., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers (2009) N. Engl. J. Med., 361, pp. 123-134 16 false true Reference 2241577 /api/reference/2241577 17. Rottenberg, S., Nygren, A.O.H., Pajic, M., van Leeuwen, F.W.B., van der Heijden, I., van de Wetering, K., Liu, X., Borst, P., Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer (2007) Proc. Natl. Acad. Sci. U. S. A., 104, pp. 12117-12122 17 false true Reference 2241578 /api/reference/2241578 18. Zander, S.A.L., Kersbergen, A., van der Burg, E., de Water, N., van Tellingen, O., Gunnarsdottir, S., Jaspers, J.E., Rottenberg, S., Sensitivity and acquired resistance of BRCA1 18 false true Reference 2241579 /api/reference/2241579 19. p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan (2010) Cancer Res., 70, pp. 1700-1710 19 false true Reference 2241580 /api/reference/2241580 20. Pajic, M., Iyer, J.K., Kersbergen, A., van der Burg, E., Nygren, A.O.H., Jonkers, J., Borst, P., Rottenberg, S., Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer (2009) Cancer Res., 69, pp. 6396-6404 20 false true Reference 2241581 /api/reference/2241581 21. Szakacs, G., Paterson, J.K., Ludwig, J.A., Booth-Genthe, C., Gottesman, M.M., Targeting multidrug resistance in cancer (2006) Nat. Rev. Drug Discov., 5, pp. 219-234 21 false true Reference 2241582 /api/reference/2241582 22. Szakács, G., Annereau, J.-P., Lababidi, S., Shankavaram, U., Arciello, A., Bussey, K.J., Reinhold, W., Gottesman, M.M., Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells (2004) Cancer Cell, 6, pp. 129-137 22 false true Reference 2241583 /api/reference/2241583 23. Türk, D., Hall, M.D., Chu, B.F., Ludwig, J.A., Fales, H.M., Gottesman, M.M., Szakács, G., Identification of compounds selectively killing multidrug-resistant cancer cells (2009) Cancer Res., 69, pp. 8293-8301 23 false true Reference 2241584 /api/reference/2241584 24. Füredi, A., Tóth, S., Szebényi, K., Pape, V.F.S., Türk, D., Kucsma, N., Cervenák, L., Szakács, G., Identification and validation of compounds selectively killing resistant cancer: delineating cell line specific effects from P-glycoprotein-induced toxicity (2016) Mol. Cancer Ther., , molcanther.0333.2016 24 false true Reference 2241585 /api/reference/2241585 25. Szakács, G., Hall, M.D., Gottesman, M.M., Boumendjel, A., Kachadourian, R., Day, B.J., Baubichon-Cortay, H., Di Pietro, A., Targeting the achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance (2014) Chem. Rev., 114, pp. 5753-5774 25 false true Reference 2241586 /api/reference/2241586 26. Fang, L., Zhang, G., Li, C., Zheng, X., Zhu, L., Xiao, J.J., Szakacs, G., Sun, D., Discovery of a daunorubicin analogue that exhibits potent antitumor activity and overcomes P-gp-mediated drug resistance (2006) J. Med. Chem., 49, pp. 932-941 26 false true Reference 2241587 /api/reference/2241587 27. Weiss, R.B., The anthracyclines: will we ever find a better doxorubicin? (1992) Semin. Oncol., 19, pp. 670-686 27 false true Reference 2241588 /api/reference/2241588 28. Handbook of Cancer Chemotherapy 8th edition - Textbooks.com (2011), http://www.textbooks.com/Handbook-of-Cancer-Chemotherapy-8th-Edition/9781608317820/Roland-T-Skeel-and-Samir-Khleif.php, (9781608317820, accessed January 2, 2017) 28 false true Reference 2241589 /api/reference/2241589 29. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity (2004) Pharmacol. Rev., 56, pp. 185-229 29 false true Reference 2241590 /api/reference/2241590 30. Barenholz, Y., Doxil®—the first FDA-approved nano-drug: lessons learned (2012) J. Control. Release Off. J. Control. Release Soc., 160, pp. 117-134 30 false true Reference 2241591 /api/reference/2241591 31. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Barenholz, Y., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes (1994) Cancer Res., 54, pp. 987-992 31 false true Reference 2241592 /api/reference/2241592 32. Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R.K., McDonald, D.M., Openings between defective endothelial cells explain tumor vessel leakiness (2000) Am. J. Pathol., 156, pp. 1363-1380 32 false true Reference 2241593 /api/reference/2241593 33. Bassermann, R., Changes of vascular pattern of tumors and surrounding tissue during different phases of metastatic growth (1986) Recent Results Cancer Res. Fortschritte Krebsforsch. Progres Dans Rech. Sur Cancer., 100, pp. 256-267 33 false true Reference 2241594 /api/reference/2241594 34. Huang, S.K., Lee, K.D., Hong, K., Friend, D.S., Papahadjopoulos, D., Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice (1992) Cancer Res., 52, pp. 5135-5143 34 false true Reference 2241595 /api/reference/2241595 35. Vaage, J., Mayhew, E., Lasic, D., Martin, F., Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes (1992) Int. J. Cancer, 51, pp. 942-948 35 false true Reference 2241596 /api/reference/2241596 36. Vaage, J., Donovan, D., Mayhew, E., Abra, R., Huang, A., Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes (1993) Cancer, 72, pp. 3671-3675 36 false true Reference 2241597 /api/reference/2241597 37. Colbern, G.T., Hiller, A.J., Musterer, R.S., Pegg, E., Henderson, I.C., Working, P.K., Significant increase in antitumor potency of doxorubicin Hc1 by its encapsulation in pegylated liposomes (1999) J. Liposome Res., 9, pp. 523-538 37 false true Reference 2241598 /api/reference/2241598 38. Working, P.K., Dayan, A.D., Pharmacological-toxicological expert report. CAELYX. (stealth liposomal doxorubicin HCl) (1996) Hum. Exp. Toxicol., 15, pp. 751-785 38 false true Reference 2241599 /api/reference/2241599 39. Cabanes, A., Tzemach, D., Goren, D., Horowitz, A.T., Gabizon, A., Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model (1998) Clin. Cancer Res. Off. J. Am. Assoc, 4, pp. 499-505 39 false true Reference 2241600 /api/reference/2241600 40. Mazurchuk, R., Glaves, D., Raghavan, D., Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer (1997) Clin. Cancer Res. Off. J. Am. Assoc, 3, pp. 1635-1641 40 false true Reference 2241601 /api/reference/2241601 41. Vaage, J., Barberá-Guillem, E., Abra, R., Huang, A., Working, P., Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts (1994) Cancer, 73, pp. 1478-1484 41 false true Reference 2241602 /api/reference/2241602 42. Vail, D.M., Amantea, M.A., Colbern, G.T., Martin, F.J., Hilger, R.A., Working, P.K., Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies (2004) Semin. Oncol., 31, pp. 16-35 42 false true Reference 2241603 /api/reference/2241603 43. O'Shaughnessy, J.A., Pegylated liposomal doxorubicin in the treatment of breast cancer (2003) Clin. Breast Cancer., 4, pp. 318-328 43 false true Reference 2241604 /api/reference/2241604 44. Mechetner, E., Kyshtoobayeva, A., Zonis, S., Kim, H., Stroup, R., Garcia, R., Parker, R.J., Fruehauf, J.P., Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin (1998) Clin. Cancer Res. Off. J. Am. Assoc, 4, pp. 389-398 44 false true Reference 2241605 /api/reference/2241605 45. Buerstedde, J.M., Reynaud, C.A., Humphries, E.H., Olson, W., Ewert, D.L., Weill, J.C., Light chain gene conversion continues at high rate in an ALV-induced cell line (1990) EMBO J., 9, pp. 921-927 45 false true Reference 2241606 /api/reference/2241606 46. Vandenberg, C.J., Gergely, F., Ong, C.Y., Pace, P., Mallery, D.L., Hiom, K., Patel, K.J., BRCA1-independent ubiquitination of FANCD2 (2003) Mol. Cell, 12, pp. 247-254 46 false true Reference 2241607 /api/reference/2241607 47. Saal, L.H., Gruvberger-Saal, S.K., Persson, C., Lövgren, K., Jumppanen, M., Staaf, J., Jönsson, G., Borg, A., Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair (2008) Nat. Genet., 40, pp. 102-107 47 false true Reference 2241608 /api/reference/2241608 48. Szakács, G., Gottesman, M.M., Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer (2004) Mol. Interv., 4, p. 323 48 false true Reference 2241609 /api/reference/2241609 49. Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., Scambia, G., Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (“hand-foot” syndrome) (2007) Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 18, pp. 1159-1164 49 false true Reference 2241610 /api/reference/2241610 50. Martin, R.W., Orelli, B.J., Yamazoe, M., Minn, A.J., Takeda, S., Bishop, D.K., RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors (2007) Cancer Res., 67, pp. 9658-9665 50 false true Reference 2241611 /api/reference/2241611 51. Sparano, J.A., Makhson, A.N., Semiglazov, V.F., Tjulandin, S.A., Balashova, O.I., Bondarenko, I.N., Bogdanova, N.V., Rackoff, W.R., Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study (2009) J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 27, pp. 4522-4529 51 false true Reference 2241612 /api/reference/2241612 52. Perez, A.T., Domenech, G.H., Frankel, C., Vogel, C.L., Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience (2002) Cancer Investig., 20, pp. 22-29 52 false true Reference 2241613 /api/reference/2241613 53. Hamilton, A., Biganzoli, L., Coleman, R., Mauriac, L., Hennebert, P., Awada, A., Nooij, M., de Valeriola, D., EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer (2002) Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 13, pp. 910-918 53 false true Reference 2241614 /api/reference/2241614 54. Lao, J., Madani, J., Puértolas, T., Alvarez, M., Hernández, A., Pazo-Cid, R., Artal, A., Antón Torres, A., Liposomal Doxorubicin in the treatment of breast cancer patients: a review (2013) J. Drug Deliv., 2013, p. 456409 54 false true Reference 2241615 /api/reference/2241615 55. Pastan, I., Gottesman, M.M., Multidrug resistance (1991) Annu. Rev. Med., 42, pp. 277-286 55 false true Reference 2241616 /api/reference/2241616 56. Seynhaeve, A.L.B., Dicheva, B.M., Hoving, S., Koning, G.A., ten Hagen, T.L.M., Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging (2013) J. Control. Release Off. J. Control. Release Soc., 172, pp. 330-340 56 false true Reference 2241617 /api/reference/2241617 57. Krieger, M.L., Konold, A., Wiese, M., Jaehde, U., Bendas, G., Targeted doxorubicin-liposomes as a tool to circumvent P-gp-mediated resistance in ovarian carcinoma cells (2010) ResearchGate, 48, pp. 442-444 57 false true Reference 2241618 /api/reference/2241618 58. Batrakova, E.V., Li, S., Brynskikh, A.M., Sharma, A.K., Li, Y., Boska, M., Gong, N., Kabanov, A.V., Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers (2010) J. Control. Release, 143, pp. 290-301 58 false true Reference 2241619 /api/reference/2241619 59. Iyer, A.K., Singh, A., Ganta, S., Amiji, M.M., Role of integrated cancer nanomedicine in overcoming drug resistance (2013) Adv. Drug Deliv. Rev., 65, pp. 1784-1802 59 false true Reference 2241620 /api/reference/2241620 60. Lelle, M., Freidel, C., Kaloyanova, S., Tabujew, I., Schramm, A., Musheev, M., Niehrs, C., Peneva, K., Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity (2017) Eur. J. Med. Chem., 130, pp. 336-345 60 false true Reference 2241621 /api/reference/2241621 61. Kunjachan, S., B?au?, A., M?ckel, D., Theek, B., Kiessling, F., Etrych, T., Ulbrich, K., Lammers, T., Overcoming cellular multidrug resistance using classical nanomedicine formulations (2012) Eur. J. Pharm. Sci., 45, pp. 421-428 61 false true Reference 2241622 /api/reference/2241622 62. Gabizon, A.A., Patil, Y., La-Beck, N.M., New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy (2016) Drug Resist. Updat., 29, pp. 90-106 62 false true Reference 2241623 /api/reference/2241623 63. Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L., Holt, J.T., Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression (1995) Nat. Genet., 9, pp. 444-450 63 false true Reference 2241624 /api/reference/2241624 64. Turner, N.C., Reis-Filho, J.S., Russell, A.M., Springall, R.J., Ryder, K., Steele, D., Savage, K., Tutt, A.N., BRCA1 dysfunction in sporadic basal-like breast cancer (2007) Oncogene, 26, pp. 2126-2132 64 false true Reference 2241625 /api/reference/2241625 65. Turner, N., Tutt, A., Ashworth, A., Hallmarks of “BRCAness” in sporadic cancers (2004) Nat. Rev. Cancer, 4, pp. 814-819 65 false true Reference 2241626 /api/reference/2241626 66. Esteller, M., Silva, J.M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Herman, J.G., Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors (2000) J. Natl. Cancer Inst., 92, pp. 564-569 66 false true Reference 2241627 /api/reference/2241627 67. Pritchard, C.C., Mateo, J., Walsh, M.F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Nelson, P.S., Inherited DNA-repair gene mutations in men with metastatic prostate cancer (2016) N. Engl. J. Med., 375, pp. 443-453 67 false true Reference 2241628 /api/reference/2241628 68. O'Brien, M.E.R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., CAELYX Breast Cancer Study Group, Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer (2004) Ann. Oncol. Off. J. Eur. Soc. Med. Oncol., 15, pp. 440-449 68 false true Reference 2241629 /api/reference/2241629 69. Harker, W.G., MacKintosh, F.R., Sikic, B.I., Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs (1983) Cancer Res., 43, pp. 4943-4950 69 false true Reference 2241630 /api/reference/2241630 70. Al-Batran, S.-E., Güntner, M., Pauligk, C., Scholz, M., Chen, R., Beiss, B., Stopatschinskaja, S., Jäger, E., Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials (2010) Br. J. Cancer, 103, pp. 1518-1523 70 false true Reference 2241631 /api/reference/2241631 71. Al-Batran, S.-E., Bischoff, J., von Minckwitz, G., Atmaca, A., Kleeberg, U., Meuthen, I., Morack, G., Jager, E., The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial (2006) Br. J. Cancer, 94, pp. 1615-1620 71 false true Reference 2241632 /api/reference/2241632 72. Safra, T., Borgato, L., Nicoletto, M.O., Rolnitzky, L., Pelles-Avraham, S., Geva, R., Donach, M.E., Muggia, F., BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin (2011) Mol. Cancer Ther., 10, pp. 2000-2007 72 false true Reference 2241633 /api/reference/2241633 73. Kaye, S.B., Lubinski, J., Matulonis, U., Ang, J.E., Gourley, C., Karlan, B.Y., Amnon, A., Kaufman, B., Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (2012) J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 30, pp. 372-379 73 false true Reference 2241634 /api/reference/2241634 74. Rottenberg, S., Jaspers, J.E., Kersbergen, A., van der Burg, E., Nygren, A.O.H., Zander, S.A.L., Derksen, P.W.B., Jonkers, J., High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (2008) Proc. Natl. Acad. Sci., 105, pp. 17079-17084 74 false true Reference 2241635 /api/reference/2241635 75. Murai, J., Huang, S.N., Das, B.B., Dexheimer, T.S., Takeda, S., Pommier, Y., Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells (2012) J. Biol. Chem., 287, pp. 12848-12857 75 false true Reference 2241636 /api/reference/2241636 76. Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J.H., Pommier, Y., Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition (2014) J. Pharmacol. Exp. Ther., 349, pp. 408-416 76 false true Reference 2241637 /api/reference/2241637 77. Lohse, I., Borgida, A., Cao, P., Cheung, M., Pintilie, M., Bianco, T., Holter, S., Hedley, D.W., BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts (2015) Br. J. Cancer, 113, pp. 425-432 77 false true Reference 2241638 /api/reference/2241638 78. Lesnock, J.L., Darcy, K.M., Tian, C., Deloia, J.A., Thrall, M.M., Zahn, C., Armstrong, D.K., Krivak, T.C., BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study (2013) Br. J. Cancer, 108, pp. 1231-1237 78 false true Reference 2241639 /api/reference/2241639 79. Stefansson, O.A., Villanueva, A., Vidal, A., Martí, L., Esteller, M., BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer (2012) Epigenetics., 7, pp. 1225-1229 79 false true Reference 2241640 /api/reference/2241640 80. Turner, N.C., Tutt, A.N.J., Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence? (2012) Breast Cancer Res. BCR., 14, p. 115 80 false true Reference 2241641 /api/reference/2241641 81. Byrski, T., Gronwald, J., Huzarski, T., Grzybowska, E., Budryk, M., Stawicka, M., Mierzwa, T., Narod, S., Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy (2010) J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 28, pp. 375-379 81 false true Reference 2241642 /api/reference/2241642 82. Byrski, T., Dent, R., Blecharz, P., Foszczynska-Kloda, M., Gronwald, J., Huzarski, T., Cybulski, C., Narod, S.A., Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer (2012) Breast Cancer Res. BCR., 14, p. R110 82 false true Reference 2241643 /api/reference/2241643 83. Caestecker, K.W., Van de Walle, G.R., The role of BRCA1 in DNA double-strand repair: past and present (2013) Exp. Cell Res., 319, pp. 575-587 83 false true Reference 2241644 /api/reference/2241644 84. Raut, L.S., Novel formulation of cytarabine and daunorubicin: a new hope in AML treatment (2015) South Asian J. Cancer, 4, pp. 38-40 84 false true /api/publication/3251042 Furedi A et al. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.. (2017) JOURNAL OF CONTROLLED RELEASE 0168-3659 1873-4995 261 287-296<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10032787"><a href="/gui2/?type=authors&mode=browse&sel=10032787" target="_blank">Furedi A (<span class="authorship-author-name">Füredi András</span> <span class="authorAux-mtmt"> Tumorbiológia, drog rezisztencia</span>) </a> </span> <span class="author-affil"><span title="MTA Research Centre for Natural Sciences">MTA TTK</span>/Institute of Enzymology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10022032"><a href="/gui2/?type=authors&mode=browse&sel=10022032" target="_blank">Szebenyi K (<span class="authorship-author-name">Szebényi Kornélia</span> <span class="authorAux-mtmt"> Őssejtbiológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10032964"><a href="/gui2/?type=authors&mode=browse&sel=10032964" target="_blank">Toth S (<span class="authorship-author-name">Tóth Szilárd</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10050407"><a href="/gui2/?type=authors&mode=browse&sel=10050407" target="_blank">Cserepes M (<span class="authorship-author-name">Cserepes Tamás Mihály</span> <span class="authorAux-mtmt"> tumorbiológia, molekuláris biológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10053930"><a href="/gui2/?type=authors&mode=browse&sel=10053930" target="_blank">Hamori L (<span class="authorship-author-name">Hámori Lilla</span> <span class="authorAux-mtmt"> Tumorsejtbiológia</span>) </a> </span> <span class="author-affil"><span title="MTA Research Centre for Natural Sciences">MTA TTK</span>/Institute of Enzymology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10053931"><a href="/gui2/?type=authors&mode=browse&sel=10053931" target="_blank">Nagy V (<span class="authorship-author-name">Nagy Veronika</span> <span class="authorAux-mtmt"> Tumorbiológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10059335"><a href="/gui2/?type=authors&mode=browse&sel=10059335" target="_blank">Karai E (<span class="authorship-author-name">Karai Edina</span> <span class="authorAux-mtmt"> onkológia</span>) </a> </span> <span class="author-affil"><span title="University of Veterinary Medicine Budapest">UVMB</span>/Department of Patophysiology and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002293"><a href="/gui2/?type=authors&mode=browse&sel=10002293" target="_blank">Vajdovich P (<span class="authorship-author-name">Vajdovich Péter</span> <span class="authorAux-mtmt"> Állatorvosi belgyógyászat, laboratóriumi diagno...</span>) </a> </span> <span class="author-affil"><span title="University of Veterinary Medicine Budapest">UVMB</span>/Department of Patophysiology and Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10014805"><a href="/gui2/?type=authors&mode=browse&sel=10014805" target="_blank">Imre T (<span class="authorship-author-name">Imre Timea</span> <span class="authorAux-mtmt"> Tömegspektrometria</span>) </a> </span> <span class="author-affil"><span title="MTA Research Centre for Natural Sciences">MTA TTK</span>/Instrumentation Center</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10014589"><a href="/gui2/?type=authors&mode=browse&sel=10014589" target="_blank">Szabo P (<span class="authorship-author-name">Szabó Pál Tamás</span> <span class="authorAux-mtmt"> Tömegspektrometria</span>) </a> </span> <span class="author-affil"><span title="MTA Research Centre for Natural Sciences">MTA TTK</span>/Instrumentation Center</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10026660"><a href="/gui2/?type=authors&mode=browse&sel=10026660" target="_blank">Szuts D (<span class="authorship-author-name">Szüts Dávid</span> <span class="authorAux-mtmt"> Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="MTA Research Centre for Natural Sciences">MTA TTK</span>/Institute of Enzymology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10009941"><a href="/gui2/?type=authors&mode=browse&sel=10009941" target="_blank">Tovari J (<span class="authorship-author-name">Tóvári József</span> <span class="authorAux-mtmt"> Daganatbiológia, áttétképzés</span>) </a> </span> <span class="author-affil">National Institute of Oncology</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001932"><a href="/gui2/?type=authors&mode=browse&sel=10001932" target="_blank">Szakacs G ✉ (<span class="authorship-author-name">Szakács Gergely</span> <span class="authorAux-mtmt"> Biokémia, membránbiológia</span>) </a> </span> <span class="author-affil"><span title="MTA Research Centre for Natural Sciences">MTA TTK</span>/Institute of Enzymology</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;3251042" target="_blank">Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.</a></div> <div> <span class="journal-title">JOURNAL OF CONTROLLED RELEASE</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0168-3659">0168-3659</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1873-4995">1873-4995</a>)</span>: <span class="journal-volume">261</span> <span class="page"> pp 287-296 </span> <span class="year">(2017)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Language: English | </span> <span class="identifiers"> <span class="id identifier oa_PAY" title=" Pay "> <a style="color:blue" title="10.1016/j.jconrel.2017.07.010" target="_blank" href="https://doi.org/10.1016/j.jconrel.2017.07.010"> DOI </a> </span> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:black" title="74947" target="_blank" href="http://real.mtak.hu/74947"> REAL </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000406860400025" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000406860400025"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85023647981" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85023647981"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="28700899" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28700899&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_NONE" title=" None "> <a style="color:blue" title="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023647981&doi=10.1016%2Fj.jconrel.2017.07.010&partnerID=40&md5=4f2050aa52706d40d3ec2a4bb16c2111" target="_blank" href="https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023647981&doi=10.1016%2Fj.jconrel.2017.07.010&partnerID=40&md5=4f2050aa52706d40d3ec2a4bb16c2111"> Other URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Journal subject: Scopus - Pharmaceutical Science&nbsp;&nbsp;&nbsp;Rank:&nbsp;D1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="" class="citingPub-count">Citing papers: 94</span> | Independent citation: 70 | Self citation: 24 | Unknown citation: 0 | Number of citations in WoS: 72 | Number of citations in Scopus:&nbsp;92 | WoS/Scopus assigned:&nbsp;93 | Number of citations with DOI:&nbsp;92 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;3251042&sort=publishedYear,desc&sort=title"> Number of cited publications: 8 </a> </div> <div class="mtid"><span class="long-pub-mtid">Publication: 3251042</span> | <span class="status-data status-VALIDATED"> Validated </span> <span class="oldId">Old id: 3251042</span> | Core Citing | <span class="type-subtype">Journal Article ( Article ) </span> | <span class="pub-category">Scientific</span> | <span class="publication-sourceOfData">MEDLINE</span> </div> <div class="lastModified">Last Modified: 2020.12.22. 21:31 Admin Szuper (admin) </div> <div class="lockedBy">Centrally managed 2026.04.14. 15:01 Éva Pécsi (MTMT Közp 2,3, admin) </div> </div></div>